It is important to note that subgroups of breast cancer and high-grade serous ovarian carcinoma patients with high SLFN11 expression showed a prominent association with immune activation after treatment with chemotherapy (59,60). This evidence concerns the gene SLFN11 and ovarian serous carcinoma.